Sanofi and Aviesan Renew their Agreement to Accelerate Research in France

09/27/2013 09:15:59 AM
Sanofi and Aviesan Renew their Agreement to Accelerate Research in France
[PR Newswire TOD Wire]

Published Date: September 27, 2013 09:15:00 AM EDT

PR Newswire/Les Echos/


Sanofi and Aviesan Renew their Agreement to Accelerate Research in France

- Three-year renewal of the cooperation protocol -

Paris, France - September 27, 2013 - Sanofi (EURONEXT: SAN and NYSE: SNY) and
Aviesan(1), the French National Alliance for Life Sciences and Health today
announced that they have renewed for a period of three years the cooperation
protocol signed in 2010.The aim is to contribute to the development of new
treatments that target unmet medical needs, including those in the field of
rare diseases, to participate to the excellence and consolidation of research
in French industry on an international level. Special emphasis will be put on
translational research projects that bring together clinical and medical teams
with fundamental research teams to translate research successes into medical

"As well as strengthening existing ties, this new agreement will allow us to
explore other avenues of research," said Professor André Syrota, President of
Aviesan. "Translational research combines clinical and basic research,
underscoring the critical importance of linking industrial and academic

Several projects under this new protocol are under discussion, including the
creation of centers of excellence as part of future investments, particularly
in collaboration with IHUs (University Hospital Institutes) and IRTs
(Technological Research Institutes).

"With the signing of several projects between Sanofi and Aviesan during the
past three years, Sanofi has become the leading private partner of academic
research in the life sciences," said Dr Elias Zerhouni, President, Global
Research & Development, Sanofi. "Strategic and operational committees have
worked tirelessly to achieve this convergence of the best in French academic
excellence and our own teams. We all committed to pursuing these vital
interactions in order to accelerate scientific discoveries for the benefit
of patients."

The new cooperation between Aviesan and Sanofi research teams will also spur
the development of technology platforms to finance the work of researchers
(e.g. the ATIP-Avenirs program), CIFRE fellows, post-docs, and staff

A Strategy Committee and an Operational Steering Committee, each consisting of
eight directors divided equally between Aviesan and Sanofi, will coordinate
interactions between the different players, as well as preparing and
validating projects and monitoring their implementation.

(1) An alliance between CEA, the CNRS, INRA, INRIA, Inserm, the Institut
Pasteur, the IRD, the Conference of University Presidents and the Conference
of Managing Directors of regional and university hospitals.

About the collaboration between Sanofi and Aviesan since 2010
The cooperation protocol signed in 2010 between Sanofi and Aviesan is based on
three pillars. First, collaboration agreements with Aviesan research teams.
Second, the creation of teams of young researchers supported by additional
funding from the ATIP-Avenirs program, a joint CNRS and INSERM initiative.
Third, Sanofi is a member of the COPIO (interagency Steering Committee) tasked
with setting up and bringing to maturity inter-agency projects that help with
medical progress and the development of the healthcare industry, through which
Sanofi has funded several projects.

In three years, Sanofi has signed 15 collaborative projects with Aviesan's
French teams of academic excellence, as well as providing additional funding
to 16 young scientists who won ATIP-Avenirs grants and investing in four
COPIO projects. Over 10 million euros were invested by Sanofi in 2012 for
these collaborations.

About Aviesan - French National Alliance for Life Sciences and Health
France's National Alliance for Life Sciences and Health (Aviesan) encompasses
the CEA, CNRS, INRA, INRIA, INSERM, Institut Pasteur, IRD, the CPU and the
Conference of Managing Directors of regional and university hospitals, as well
as 10 associate members: Ariis, CIRAD, EFS, Fondation Mérieux, Ineris, the
Curie Institute, IRSN, IRBA, Institut Mines-Telecom and Unicancer. Aviesan
aims to develop a seamless continuum from basic research to practical
applications at the very highest level in all areas of life sciences and
healthcare research.
The National Alliance for Life Sciences and Health is organized into 10
multi-organization thematic institutes that coordinate the research and are
tasked with providing an audit of French research on the basis of major

About Sanofi
Sanofi, an integrated global healthcare leader, discovers, develops and
distributes therapeutic solutions focused on patients' needs. Sanofi has core
strengths in the field of healthcare with seven growth platforms: diabetes
solutions, human vaccines, innovative drugs, consumer healthcare, emerging
markets, animal health and the new Genzyme. Sanofi is listed in Paris
(EURONEXT: SAN) and in New York (NYSE: SNY).

Forward-Looking Statements - Sanofi
This press release contains forward-looking statements as defined in the
Private Securities Litigation Reform Act of 1995, as amended. Forward-looking
statements are statements that are not historical facts. These statements
include projections and estimates and their underlying assumptions, statements
regarding plans, objectives, intentions and expectations with respect to
future financial results, events, operations, services, product development
and potential, and statements regarding future performance. Forward-looking
statements are generally identified by the words "expects", "anticipates",
"believes","intends", "estimates", "plans" and similar expressions. Although
Sanofi's management believes that the expectations reflected in such forward-
looking statements are reasonable, investors are cautioned that forward-
looking information and statements are subject to various risks and
uncertainties, many of which are difficult to predict and generally beyond
the control of Sanofi, that could cause actual results and developments to
differ materially from those expressed in, or implied or projected by, the
forward-looking information and statements. These risks and uncertainties
include among other things, the uncertainties inherent in research and
development, future clinical data and analysis, including post marketing,
decisions by regulatory authorities, such as the FDA or the EMA, regarding
whether and when to approve any drug, device or biological application that
may be filed for any such product candidates as well as their decisions
regarding labeling and other matters that could affect the availability or
commercial potential of such product candidates, the absence of guarantee
that the product candidates if approved will be commercially successful,
the future approval and commercial success of therapeutic alternatives,
the Group's ability to benefit from external growth opportunities, trends in
exchange rates and prevailing interest rates, the impact of cost containment
policies and subsequent changes thereto, the average number of shares
outstanding as well as those discussed or identified in the
public filings with the SEC and the AMF made by Sanofi, including those listed
under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking
Statements" in Sanofi's annual report on Form 20-F for the year ended December
31, 2012. Other than as required by applicable law, Sanofi does not undertake
any obligation to update or revise any forward-looking information or
statements, notably Articles 223-1 et seq. of the general regulations of the


Sanofi Aviesan
Laurence Bollack Priscille Rivière
Tel: 01 53 77 46 46 Tel: 01 44 23 60 97

The content and accuracy of news releases published on this site and/or
distributed by PR Newswire or its partners are the sole responsibility of the
originating company or organisation. Whilst every effort is made to ensure the
accuracy of our services, such releases are not actively monitored or reviewed
by PR Newswire or its partners and under no circumstances shall PR Newswire or
its partners be liable for any loss or damage resulting from the use of such
information. All information should be checked prior to publication. 

No votes yet